Fertility on demand
Read the latest issue of Works in Progress here. The gender pay gap has barely changed since the early 2000s. In the US women who work full time earn 84 percent of what men earn. Twenty years ago they earned 80 percent. One of the main reasons for this is that women spend a lot […]
STAT+: Eli Lilly shares fall as competitor Novo notches coverage win for obesity drug
Shares of Eli Lilly dropped in pre-market trading Thursday, as competitor Novo Nordisk secured a major win on insurance coverage of its obesity drug and as Lilly reported first-quarter earnings that fell short of what investors wanted to see. CVS Caremark, the largest pharmacy benefit manager in the U.S., announced Thursday that starting in July, […]
Oral, Injected Semaglutide May Pose Distinct Eye Risks
The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which also identified differences based on sex, age, and timing of onset. Medscape Medical News
Podcast: How to Control the Side Effects of GLP-1 Drugs
Can “Ozempic face,” gastrointestinal distress, and nausea be mitigated? This episode features audio from https://nutritionfacts.org/video/how-to-control-the-side-effects-including-ozempic-face-of-glp-1-drugs/ Visit the video page for all sources and doctor’s notes related to this podcast. https://NutritionFacts.org • Subscribe: https://nutritionfacts.org/subscribe • Donate: https://nutritionfacts.org/donate • Podcast : https://nutritionfacts.org/audio • Books: https://nutritionfacts.org/books • Shop: https://drgreger.org • Facebook: https://www.facebook.com/NutritionFacts.org • Twitter: https://twitter.com/nutrition_facts • Instagram: https://www.instagram.com/nutrition_facts_org
CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans – CNBC
CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans CNBC Novo Nordisk announces that CVS Caremark®, the country’s largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies PR Newswire Eli Lilly shares fall as competitor Novo notches coverage win for […]
STAT+: Pharmalittle: We’re reading about a WHO plan to back obesity drugs, a big win for Novo Nordisk, and more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list […]
Healthify shifts gears to incorporate weight-loss drugs, cash in on anti-obesity boom
Healthify is banking on the rise of GLP-1 weight-loss drugs in India, integrating them with lifestyle coaching. The firm anticipates strong revenue growth, aiming for a 20% increase, while addressing side-effects and weight maintenance post-treatment.
Fat jabs can treat liver disease affecting one in five people, finds trial
FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of patients with non-alcoholic fatty liver disease. GettyFat jabs can cut inflammation in two thirds of patients with non-alcoholic fatty liver disease[/caption] Nonalcoholic Fatty Liver Disease (NAFLD) a buildup of fat in the liver […]
Can weight loss drugs prevent breast cancer recurrence?
Researchers in Dallas want to know if the class of drugs, GIP/GLP-1 receptor agonists, might be a secret weapon in the fight against breast cancer.
Semaglutide effectively treats liver disease in two thirds of patients, research finds
Results from the ESSENCE Phase III clinical trial published in the New England Journal of Medicine show treating patients with semaglutide can halt and even reverse liver disease.